October 19, 2022 | FDA Grants Fast Track Designation to Tvardi Therapeutics’ TTI-101 for...
September 8, 2022 | Tvardi Therapeutics to Present at the Morgan Stanley 20th Annual Global...
May 26, 2022 | Tvardi Therapeutics’ TTI-101 Receives Orphan Drug Designation for Idiopathic..
Tvardi Therapeutics is a private, clinical stage biotechnology company developing a new class of breakthrough medicines for diverse cancers and chronic inflammatory and fibrotic diseases. Tvardi is focused on the development of orally delivered, small molecule inhibitors of STAT3, a key signaling molecule positioned at the intersection of many disease pathways.
Science
Developing novel inhibitors of STAT3, a molecule implicated in the initiation and progression of cancer and fibrosis.
Team
Tvardi Therapeutics is led by a group of experienced entrepreneurs, innovative scientists & dedicated physicians.
Tvardi Named 2021 Winner of Fierce 15 Biotech
Fierce Biotech has named Tvardi Therapeutics as one of 2021’s Fierce 15 biotechnology companies, designating it as one of the most promising biotechnology companies in the industry.